STORM Therapeutics
PrivateLast Round
Series C
Apr 16, 2026
Est. Valuation
$50.5M
Total Funding Raised
$126.42M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
STORM Therapeutics is a biotechnology company that develops small molecule therapies targeting RNA modifying enzymes for the treatment of cancer and other immune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
STORM Therapeutics Comparables
Compare STORM Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EPICS Therapeutics | 88% | |
| Accent Therapeutics | 88% | |
| Expansion Therapeutics | 83% |
STORM Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 16, 2026 | ||||
| Series B | Dec 14, 2022 | ||||
| Grant | May 3, 2022 | ||||
| Series A Extension | May 20, 2019 | ||||
| Grant | Sep 3, 2018 | ||||
Series A Extension | Jan 8, 2018 |
STORM Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| IP Group | Series B, Series A Extension, Series C |
| Seroba Life Sciences | Series B, Series A Extension |
| Taiho Ventures | Series A Extension, Series C, Series B |
| M Ventures | Series A Extension, Series C, Series A, Series B |
| UKRI Innovate UK | Grant |
| Merck KGaA | Series B, Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
$56M round completed.
- Feb 12, 2026
Collaborating with Sygnature Discovery on DHX9 inhibitor program.
STORM Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about STORM Therapeutics's valuation, stock price, and market status.
Is STORM Therapeutics a public or private company?
STORM Therapeutics is a private company.
What is the current stock price of STORM Therapeutics?
STORM Therapeutics is a private company, so its shares have no public market price. Caplight tracks STORM Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is STORM Therapeutics worth (valuation)?
STORM Therapeutics's valuation is estimated at $50.5M based on funding round data.
Can I buy STORM Therapeutics stock?
STORM Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was STORM Therapeutics's last funding round?
STORM Therapeutics's most recent funding round was Series C on April 16, 2026.
Who are the main investors in STORM Therapeutics?
Key investors in STORM Therapeutics include Seroba Life Sciences, M Ventures, Merck KGaA, Imperial Innovations, Cambridge Innovation Capital.
Will STORM Therapeutics IPO soon?
No public IPO plans have been announced for STORM Therapeutics.
How can I track STORM Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in STORM Therapeutics's shares on secondary markets.